Alexandria Co. for Pharmaceuticals & Chemical Industries SAE specializes in developing, manufacturing and marketing pharmaceutical products for the treatment of inflammatory, infectious, pulmonary, dermatological, cardiovascular, allergic, epileptic, gastrointestinal diseases, etc. The group also provides veterinary and medical products (adhesive tape, gauze compresses, gloves, traction kits, etc.).

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
15/09/26	EGP 1,683.95	+1.14%	4,415
14/09/26	EGP 1,664.97	-0.22%	1,583
13/09/26	EGP 1,668.70	-0.59%	2,022
10/09/26	EGP 1,678.57	+0.91%	3,415
09/09/26	EGP 1,663.45	-1.35%	2,807

End-of-day quote Egyptian Exchange

More quotes

End-of-day quote Egyptian Exchange 15/09/2026			5-day change	1st Jan Change
1,683.95 ^EGP	+1.14%		-0.13%	+110.40%

18/05	Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the Nine Months Ended March 31, 2026	CI
03/05	Alexandria pharmaceuticals 9-month profit EGP 431.2 million	RE

Market Cap	5.6B 108M 93.54M 88.45M 80.08M 150M 10.36B 151M 1.06B 406M 5.25B 406M 397M 16.75B	P/E 2024	4.86x	P/E 2025	5.7x
Enterprise Value	5.31B 103M 88.83M 84M 76.05M 143M 9.84B 144M 1B 386M 4.99B 385M 377M 15.91B	EV / Sales 2024	0.51x	EV / Sales 2025	0.71x
Free-Float	17.74%	Yield 2024	14.2%	Yield 2025	14.1%

18/05	Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the Nine Months Ended March 31, 2026	CI
03/05	Alexandria pharmaceuticals 9-month profit EGP 431.2 million	RE
14/04	Alexandria Pharmaceuticals sees FY 2026-27 net profit EGP 690 million	RE
16/02	Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the Half Year Ended December 31, 2025	CI
25/01	Alexandria pharmaceuticals H1 profit EGP 288.9 million	RE
22/10/25	Alexandria Co. For Pharmaceuticals & Chemical Industries announces Annual dividend, payable on November 06, 2025	CI
28/09/25	Alexandria Pharmaceuticals shareholders approve FY dividend EGP 62.95/share	RE
04/09/25	Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the Full Year Ended June 30, 2025	CI
10/08/25	Alexandria pharmaceuticals reports fy profit egp 405.4 million	RE
13/05/25	Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the Nine Months Ended March 31, 2025	CI
04/05/25	Alexandria Pharmaceuticals 9-Month Net Profit EGP 323.4 Million	RE
11/02/25	Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the Half Year Ended December 31, 2024	CI
18/09/24	Alexandria Co. For Pharmaceuticals & Chemical Industries Reports Earnings Results for the Full Year Ended June 30, 2024	CI

1 day	+1.14%
1 week	-0.13%
Current month	-1.11%
1 month	+29.00%
3 months	+50.18%
6 months	+110.40%
Current year	+110.40%

Alexandria Co. For Pharmaceuticals & Chemical Industries Stock

Stocks

AXPH

EGS38341C011

Pharmaceuticals

Valuation: Alexandria Co. For Pharmaceuticals & Chemical Industries

Chart: Alexandria Co. For Pharmaceuticals & Chemical Industries

Latest news: Alexandria Co. For Pharmaceuticals & Chemical Industries

Press Releases: Alexandria Co. For Pharmaceuticals & Chemical Industries

Quotes and Performance

Price Extremes

Managers and Directors: Alexandria Co. For Pharmaceuticals & Chemical Industries

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	1,621	1,710.56
1 month	1,340	1,768
Current year	701.66	1,768
1 year	651	1,768
3 years	120	1,768
5 years	85	1,768
10 years	46	1,768

Manager	Title	Age	Since
Abla Youssef Abdullah CEO	Chief Executive Officer	-	-
Mohammed Noman Salamah DFI	Director of Finance/CFO	-	-
Ahmed Fuad ADM	Chief Administrative Officer	-	-

Director	Title	Age	Since
Mustafa Abdel Monem El-Hayawan CHM	Chairman	-	-
Sherif Salah Mohammed Tahoun BRD	Director/Board Member	-	-
Abla Youssef Abdullah BRD	Director/Board Member	-	-

	2024	2025
Net sales	1.77B 34.12M 29.56M 27.95M 25.3M 47.49M 3.27B 47.85M 334M 128M 1.66B 128M 125M 5.29B	2.75B 53.08M 45.98M 43.48M 39.36M 73.88M 5.09B 74.43M 519M 200M 2.58B 199M 195M 8.23B
Net income	217M 4.18M 3.62M 3.43M 3.1M 5.82M 401M 5.86M 40.87M 15.73M 203M 15.71M 15.36M 649M	391M 7.55M 6.54M 6.18M 5.6M 10.51M 724M 10.59M 73.79M 28.39M 367M 28.36M 27.73M 1.17B
Net Debt	-149M -2.88M -2.49M -2.36M -2.14M -4.01M -276M -4.04M -28.15M -10.83M -140M -10.82M -10.58M -447M	-282M -5.44M -4.71M -4.45M -4.03M -7.57M -522M -7.62M -53.14M -20.45M -264M -20.42M -19.97M -843M

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALEXANDRIA CO. FOR PHARMACEUTICALS & CHEMICAL INDUSTRIES	+1.14%	-0.13%	+140.90%	+1,048.75%	162M
ELI LILLY AND COMPANY	-0.19%	+1.09%	+51.85%	+97.36%	1,013B
JOHNSON & JOHNSON	+0.33%	-0.71%	+50.62%	+65.50%	644B
ABBVIE INC.	+0.49%	+5.73%	+20.88%	+72.92%	465B
ROCHE HOLDING AG	-0.22%	+2.88%	+38.48%	+37.98%	352B
NOVARTIS AG	-0.07%	+1.82%	+16.57%	+23.39%	264B
ASTRAZENECA PLC	-0.31%	+2.02%	+6.15%	+10.75%	253B
AMGEN INC.	-1.53%	-4.46%	+36.90%	+44.08%	203B
NOVO NORDISK A/S	-1.60%	-5.51%	-22.30%	-58.60%	188B
GILEAD SCIENCES, INC.	+0.49%	-0.23%	+30.00%	+93.34%	181B
Average	+0.04%	-0.85%	+37.00%	+143.55%	356.39B
Weighted average by Cap.	+0.41%	+0.01%	+34.52%	+59.47%